


Therapeutic Small Molecule Regulators of RNA Transcripts

A global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations wishes to identify innovation in **small molecule regulators of RNA transcripts that are highly selective towards their targets**. There is a particular focus on **immunologically based diseases**, including, but not limited to: **rheumatoid arthritis, inflammatory bowel disease and lupus**.



Our client is seeking to identify research at an early stage of development focusing on **small molecule drugs against RNA, RNA:protein, and RNA:RNA complexes** that can specifically up- or down-regulate the expression pattern of a target of interest.

Specific Points of Interest

- Novel methods of targeting RNA to lead to a selective change (increase or decrease) in the expression of a protein of interest
- RNA specific pathways of interest include, but are not limited to: transcription, splicing pathway, translation, mRNA stability, nonsense-mediated decay
- Specific modulation of RNA transcripts for inflammatory pathways and the DNA sensing pathway are of high interest
- Modulation of specific lncRNAs or miRNAs associated with the above pathways is within scope

Out of Scope

- Oligotherapeutics e.g. siRNAs, antisense oligonucleotides
- Gene therapy approaches
- Viral delivery

Stage of Development

Opportunities from basic research to preclinical development are within scope, with research with validation in *ex vivo* and/or *in vivo* models being of highest interest.






Submission Information

Submission of one page, 200-300 word briefs are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Potential Collaborations for Academics

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include project/PhD funding and research collaborations.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **10th January 2022 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk